The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2025The BioFINDER Studies: Identifying Disease Stages and Effects of Co-morbidities in Neuronal Synuclein Disease
Study Rationale: Neuronal synuclein disease (NSD) is the underlying cause of Parkinson’s disease (PD) and similar disorders. Recently, new tests have allowed us to measure signs of NSD before symptoms...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
Study Rationale: Peptide-based drugs are attractive candidates for treating the cognitive decline associated with Parkinson’s disease (PD) because they demonstrate a robust safety profile and an...
-
, 2022Studying the Epidemiology of Parkinson’s Disease in Latin America: Learning from Underrepresented Populations
Study Rationale: Initial evidence has shown that the global distribution of Parkinson’s disease (PD) may vary; however, little is known about the prevalence of PD across large parts of the world. This...
-
Research Grant, 2016Tau Imaging in Parkinson's Disease
Study Rationale:
A substantial proportion of individuals with Parkinson's disease develop cognitive
impairment, or difficulty with thinking abilities. The basis for these changes is poorly
understood. We... -
Translational Pipeline Program, 2022Prevention of Dementia in GBA-associated Parkinson’s Disease
Study Rationale: Whereas motor symptoms can be well controlled by dopamine-enhancing drugs and deep brain stimulation, dementia represents a key milestone in the course of Parkinson’s disease (PD)...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Study Rationale: Progressive aggregation of alpha-synuclein and the subsequent loss of affected brain cells starts 10 to 20 years before the onset of Parkinson’s disease (PD) symptoms. Early diagnosis...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.